GlassScriptPhysician profile
Mckenzie Mcmanus
NPI 1194249763
$5,230.94
in general payments reported to CMS, 2019-2025
22 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,010 · 2022: $852 · 2023: $1,033 · 2024: $973 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $691.51 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $607.08 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $585.84 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $544.57 | 2022-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $387.11 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $342.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Arbor Pharmaceuticals, INC. | $226.65 | 2021-2022 | |
| Novo Nordisk INC | $201.28 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $77.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $75.55 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $53.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.85 | 2021-2025 | Jardiance |
| Lundbeck LLC | $51.88 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $42.35 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.29 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.27 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $22.13 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.22 | 2022 | |
| Astellas Pharma US INC | $16.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.98 | 2021 | |
| Genentech USA, INC. | $2.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.